The blood test measures the integrity of the cell cycle G1/S restriction point in peripheral blood lymphocytes. Dr. Nagy, the inventor of the test and scientific co-founder of Cytox Ltd, was the principal investigator of the study, which was conducted in collaboration with the Oxford Project to Investigate Memory and Aging (OPTIMA). According to Dr. Nagy, "The results of this study support the cell cycle hypothesis of Alzheimer's disease - specifically, that G1/S cell cycle regulatory failure leads to the downstream development of the characteristic pathologies of the disease, the amyloid plaques and tau tangles. Most importantly, the findings validate the use of our lymphocyte test as a biomarker of Alzheimer's disease and suggest that the test is predictive of cognitive deficit developing in MCI patients."
About Cytox Limited
Cytox is a UK company developing products and services for neurodegenerative disorders. The company provides biomarker services to pharmaceutical industry clients conducting clinical trials with drugs for the treatment of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Cytox's blood tests enable the prediction of which patients with MCI will develop AD. The biomarkers are based on the cell cycle hypothesis of AD and were invented by Dr. Zsuzsanna Nagy at the University of Oxford and the University of Birmingham. For more information about Cytox, please visit the web site at http://www.cytoxgroup.com/.
Contact: Richard Hadden, CEO: tel: +44 20 7250 4210; email: richard.hadden@cytoxgroup.com
SOURCE Cytox Limited
CONTACT: Richard Hadden, CEO of Cytox Limited, +44 20 7250 4210,
richard.hadden@cytoxgroup.com
Web site: http://www.cytoxgroup.com/
